Nuvectis Pharma FY2022 net loss $19.1M; cash $20M; NXP800 Fast Track; NXP900 IND expected 1H23

Nuvectis Pharma, Inc.

Cash and short-term investments $20.0M at Dec 31, 2022, up from $5.7M.
Net loss $19.1M vs $12.9M in 2021; R&D expense $13.2M; G&A $6.0M.
NXP800 granted Fast Track Designation for platinum-resistant, ARID1A-mutated ovarian cancer.
ENGOT and GOG Foundation to lead NXP800 Phase 1b trial in ovarian cancer.
NXP900 IND submission and Phase 1 start expected first half 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Nuvectis Pharma, Inc. reported the fiscal year ended December 31, 2022 results: net income $19.1 million.

Period: the fiscal year ended December 31, 2022
Net income: $19.1 million
Result: reported results

Exact text from the filing

Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the fiscal year ended December 31, 2022

View on SEC.gov

Browse all earnings releases →

Nuvectis Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-029405

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.